Swipe om te navigeren naar een ander artikel
Variations in treatment are the result of differences in demographic and clinical factors (e.g. anatomy), but physician and hospital factors may also contribute to treatment variation. The choice of treatment is considered important since it could lead to differences in long-term outcomes. This study explores the associations with stent choice: i.e. drug-eluting stent (DES) versus bare-metal stents (BMS) for Dutch patients diagnosed with stable or unstable coronary artery disease (CAD).
Associations with treatment decisions were based on a prospective cohort of 692 patients with stable or unstable CAD. Of those patients, 442 patients were treated with BMS or DES. Multiple logistic regression analyses were performed to identify variables associated with stent choice. Bivariate analyses showed that NYHA class, number of diseased vessels, previous percutaneous coronary intervention, smoking, diabetes, and the treating hospital were associated with stent type. After correcting for other associations the treating hospital remained significantly associated with stent type in the stable CAD population.
This study showed that several factors were associated with stent choice. While patients generally appear to receive the most optimal stent given their clinical characteristics, stent choice seems partially determined by the treating hospital, which may lead to differences in long-term outcomes.
Vaartjes I, Koopman C, Dis I van, Visseren F, Bots M. Hart- en vaatziekten in Nederland. 2013. https://www.hartstichting.nl/downloads/cijferboek-2013, 2014.
Heer F de, Groenwold R, ter Burg W, Versteegh M, Herwerden L van, Brinkman E. Openhartoperaties en percutane coronaire interventies bij patienten met hartziekten in Nederland. 2013. https://www.hartstichting.nl/downloads/cijferboek-2013. Accessed 2013.
Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009;122:581. e1. CrossRef
Austin D, Oldroyd KG, McConnachie A, et al. Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. J Public Health (Oxf). 2008;30:186–93. CrossRef
Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054. CrossRefPubMed
RIVM. Off-label use of coronary drug-eluting stents. Occurrence, safety, and effectiveness in ‘real world’ clinical practice. 2011. http://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2012/juni/Off_label_use_of_coronary_drug_eluting_stents_Occurrence_safety_and_effectiveness_in_real_world_clinical_practice, 2015.
Hill R, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess. 2004;8:1–256. CrossRef
Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–242. CrossRef
Goeree R, Bowen JM, Blackhouse G, et al. Economic evaluation of drug-eluting stents compared with bare metal stents using a large prospective study in Ontario. Int J Technol Assess Healthcare. 2009;25:196–207. CrossRef
Bowen J, Hopkins R, He Y, et al. Systematic review and cost-effectiveness analysis of drug eluting stents compared with bare metal stents for percutaneous coronary interventions in Ontario. Interim Report for the Ontario Ministry of Health and Long-term Care. 2005:170.
Kuukasjarvi P, Rasanen P, Malmivaara A, Aronen P, Sintonen H. Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis. Int J Technol Assess Healthcare. 2007;23:473–9. CrossRef
Mittmann N, Brown A, Seung SJ, et al. Drug eluting stents: an economic evaluation [Technology overview no 15]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005. p 10.
Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619. CrossRefPubMed
- Treatment variation in stent choice in patients with stable or unstable coronary artery disease
L. T. Burgers
E. A. McClellan
I. E. Hoefer
J. W. Jukema
N. H. J. Pijls
M. A. Hillaert
A. C. Stubbs
J. L. Severens
W. K. Redekop
- Bohn Stafleu van Loghum